Olink Holding AB (publ)’s (OLK) Equal Weight Rating Reaffirmed at Morgan Stanley

Olink Holding AB (publ) (NASDAQ:OLK)‘s stock had its “equal weight” rating reissued by equities researchers at Morgan Stanley in a research report issued on Tuesday, Benzinga reports. They presently have a $26.00 price objective on the stock. Morgan Stanley’s price target suggests a potential upside of 10.17% from the company’s previous close.

Separately, Canaccord Genuity Group reissued a “hold” rating and set a $26.00 price target on shares of Olink Holding AB (publ) in a research note on Tuesday.

Olink Holding AB (publ) Trading Down 1.9 %

Shares of OLK stock opened at $23.60 on Tuesday. The business’s 50-day moving average price is $23.96 and its 200-day moving average price is $22.95. Olink Holding AB has a 12 month low of $14.10 and a 12 month high of $26.01. The firm has a market capitalization of $2.93 billion, a price-to-earnings ratio of -94.40 and a beta of 0.49.

Institutional Trading of Olink Holding AB (publ)

Hedge funds have recently made changes to their positions in the company. UBS Group AG boosted its stake in shares of Olink Holding AB (publ) by 55.9% during the third quarter. UBS Group AG now owns 5,700 shares of the company’s stock valued at $69,000 after purchasing an additional 2,043 shares in the last quarter. Assetmark Inc. raised its position in shares of Olink Holding AB (publ) by 30.5% during the fourth quarter. Assetmark Inc. now owns 2,874 shares of the company’s stock worth $72,000 after acquiring an additional 672 shares during the last quarter. Tower Research Capital LLC TRC bought a new position in shares of Olink Holding AB (publ) during the third quarter worth about $76,000. Barometer Capital Management Inc. bought a new position in shares of Olink Holding AB (publ) during the fourth quarter worth about $116,000. Finally, US Bancorp DE raised its position in shares of Olink Holding AB (publ) by 874.4% during the second quarter. US Bancorp DE now owns 9,666 shares of the company’s stock worth $181,000 after acquiring an additional 8,674 shares during the last quarter. 30.19% of the stock is owned by institutional investors and hedge funds.

Olink Holding AB (publ) Company Profile

Olink Holding AB (publ) provides various products and services for the academic, government, biopharmaceutical, biotechnology, service provider, and other institutions that focuses on life science research. The company's products include Olink Explore for cardiovascular and metabolic, oncology, neurology, or inflammation diseases; Olink Target product line; Olink Flex, a low-plex applications and use-cases; and Olink Focus product line that consists of custom developed solutions for customers that has identified various proteins of interest or a protein signature to focus on.